A phase-III study to investigate the safety and efficacy of levodopa/carbidopa (ND0612H) for the treatment of Parkinson's disease.

Trial Profile

A phase-III study to investigate the safety and efficacy of levodopa/carbidopa (ND0612H) for the treatment of Parkinson's disease.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 05 Dec 2016

At a glance

  • Drugs Levodopa/carbidopa (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 05 Dec 2016 According to the NeuroDerm media release, Following the discussions with the FDA the Company has decided to discontinue this trial and will replace it with small pharmacokinetic trial for regulatory development.
    • 05 Dec 2016 Status changed from planning to discontinued, according to NeuroDerm media release.
    • 10 Nov 2016 According to a NeuroDerm media release, this trial is expected to initiate at the end of 2016 or beginning of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top